Literature DB >> 18319028

Multiple lentigines arising in resolving psoriatic plaques after treatment with etanercept.

Lucas Ana Costa1, Isabel Belinchón, Isabel Betlloch, María Pérez-Crespo, Javier Mataix.   

Abstract

Development of lentigines in zones previously affected by plaques of psoriasis has been described, and its frequency has probably been underestimated. Most cases have been described following the use of phototherapy, although other authors have observed the appearance of lentigines in patients with psoriasis treated only with topical products. It has been suggested that the mechanism involved could be an abnormal reaction to UV light or an unusual form of postinflammatory hyperpigmentation. We report the case of two patients in whom multiple lentigines appeared, confined to plaques of psoriasis after using etanercept. Development of lentigines after using biologic drugs is a phenomenon that does not appear to have been described previously. We consider that the mechanism of production of lentigines is related to psoriasis itself and not to the therapy used.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18319028

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  3 in total

1.  Lentiginoses in polycythemia vera patient: Is there a role for JAK2 (V617F) mutation?

Authors:  Tugba Kevser Uzuncakmak; Sarenur Yilmaz; Ayse Serap Karadag; Necmettin Akdeniz; Ibrahim Akalin
Journal:  JAKSTAT       Date:  2015-07-24

2.  Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature.

Authors:  Pablo Santa María; Fernando Valenzuela; Claudia Morales; Raul De la Fuente; Roberto Cullen
Journal:  Dermatol Reports       Date:  2017-10-11

3.  Multiple Lentigines Arising in Sites of Resolving Psoriatic Plaques after Treatment with Ustekinumab.

Authors:  Jeong Soo Kim; Seul Ki Lee; Ha Ryeong Ryu; Chul Hyun Yun; Jin Ok Baek; Joo Young Roh; Jong Rok Lee
Journal:  Ann Dermatol       Date:  2018-04-23       Impact factor: 1.444

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.